박영석

  #대장암#췌장암#담도암

학력

1999.02 고려대학교 의과대학원 박사학위 취득
1992.02 서울대학교 의과대학원 석사학위 취득
1986.02 서울대학교 의과대학 졸업

경력

2007.03 ~현재 삼성서울병원 혈액종양내과 교수
2014.03 ~ 2019.03 삼성서울병원 임상의학연구소장
2015.03 ~ 2017.03 삼성서울병원 혈액종양내과분과장
2003.04 ~ 2007.02 삼성서울병원 혈액종양내과 부교수
2000.12 ~ 2003.03 국립암센터 부속병원 임상시험센터 센터장
1991.03 ~ 2000.11 한림대학교 의과대학 부교수
1996.09 ~ 1997.11 미국 피츠버그 대학,
National Surgical Adjuvant Breast and Bowel Project, Consultant
1993.06 ~ 1993.09 미국 Fred Hutchinson Cancer Research Center, clinical fellow
1990.03 ~ 1991.02 서울대학병원 혈액종양내과 전임의
1987.03 ~ 1990.02 서울대학병원 내과 전공의
1986.03 ~ 1987.02 서울대학병원 인턴

논문


Front Oncol 2019 10.3389/fonc.2019.01327
Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening
Lim1, SH; Sa, JK; Lee, DW; Kim, J; Kim, ST; Park, SH; Ku, B; Park, JO; Park, YS; Lim, H; Kang, WK; Nam, DH; Lee, J

J CLIN ONCOL 2019 10.1200/JCO.19.00016
Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial
Hong1, YS; Kim, SY; Lee, JS; Nam, BH; Kim, KP; Kim, JE; Park, YS; Park, JO; Baek, JY; Kim, TY; Lee, KW; Ahn, JB; Lim, SB; Yu, CS; Kim, JC; Yun, SH; Kim, JH; Park, JH; Park, HC; Jung, KH; Kim, TW

J Cancer 2019 10.7150/jca.37610
Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial
Kim1, ST; Oh, SY; Lee, J; Kang, JH; Lee, HW; Lee, MA; Sohn, BS; Hong, JH; Park, YS; Park, JO; Lim, HY

J IMMUNOTHER 2019 10.1097/CJI.0000000000000283
LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target
Lee1, SJ; Byeon, SJ; Lee, J; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Kim, KM; Kim, ST

SCI REP-UK 2019 10.1038/s41598-019-51981-5
Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients
Bray1, SM; Lee, J; Kim, ST; Hur, JY; Ebert, PJ; Calley, JN; Wulur, IH; Gopalappa, T; Wong, SS; Qian, HR; Ting, JC; Liu, JG; Willard, MD; Novosiadly, RD; Park, YS; Park, JO; Lim, HY; Kang, WK; Aggarwal, A; Kim, HC; Reinhard, C

CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0442
Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial
Lee1, J; Kim, ST; Kim, K; Lee, H; Kozarewa, I; Mortimer, PGS; Odegaard, JI; Harrington, EA; Lee, J; Lee, T; Oh, SY; Kang, JH; Kim, JH; Kim, Y; Ji, JH; Kim, YS; Lee, KE; Kim, J; Sohn, TS; An, JY; Choi, MG; Lee, JH; Bae, JM; Kim, S; Kim, JJ; Min, YW; Min, BH; Kim, NKD; Luke, S; Kim, YH; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Talasaz, A; Hollingsworth, SJ; Kim, KM; Kang, WK

Transl Cancer Res 2019 10.21037/tcr.2019.09.27
Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs
Cho1, JH; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

Am J Transl Res 2019
Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification
Kim1, ST; Lee, IK; Rom, E; Sirkis, R; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Yayon, A; Lee, J

CANCER RES TREAT 2019 10.4143/crt.2018.379
A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
Kim1, Y; Kim, TW; Han, SW; Ahn, JB; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK

CANCER RES TREAT 2019 10.4143/crt.2018.401
Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols
Yu1, JI; Lim, D; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Rae, JM; Yoo, H; Kim, K

J Cancer 2019 10.7150/jca.30355
The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma
Yoon1, SE; Kim, JH; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

ANN ONCOL 2019 10.1093/annonc/mdz058
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial
Kim1, ST; Kang, JH; Lee, J; Lee, HW; Oh, SY; Jang, JS; Lee, MA; Sohn, BS; Yoon, SY; Choi, HJ; Hong, JH; Kim, MJ; Kim, S; Park, YS; Park, JO; Lim, HY

TRANSL ONCOL 2019 10.1016/j.tranon.2018.12.009
Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial
Kim1, ST; Lee, S; Park, M; Park, SH; Park, JO; Lim, HY; Park, YS; Kang, WK; Gangolli, EA; Shin, H; Kim, KM; Hollingsworth, SJ; Mortimer, PGS; Lee, J

PLoS One 2019 10.1371/journal.pone.0215080
Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system
Cho1, JH; Kim, JS; Kim, ST; Hong, JY; Park, JO; Park, YS; Nam, DH; Lee, DW; Lee, J

ANN SURG 2019 10.1097/SLA.0000000000002582
Anastomotic Leak Does Not Impact Oncologic Outcomes After Preoperative Chemoradiotherapy and Resection for Rectal Cancer
Jang1, JH; Kim, HC; Huh, JW; Park, YA; Cho, YB; Yun, SH; Lee, WY; Yu, JI; Park, HC; Park, YS; Park, JO

J Cancer 2019 10.7150/jca.29106
The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

SURGERY 2019 10.1016/j.surg.2018.08.026
Tumor regression grade as a clinically useful outcome predictor in patients with rectal cancer after preoperative chemoradiotherapy
Huh1, JW; Kim, HC; Kim, SH; Park, YA; Cho, YB; Yun, SH; Lee, WY; Park, HC; Choi, DH; Park, JO; Park, YS; Chun, HK

OncoTargets and therapy 2019 10.2147/OTT.S182259
Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study
Yao1, JC; Oh, DY; Qian, JM; Park, YS; Herbst, F; Ridolfi, A; Izquierdo, M; Ito, T; Jia, LQ; Komoto, I; Sriuranpong, V; Shimada, Y

OncoTargets and therapy 2019 10.2147/OTT.S187621
The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2016.348
The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-O4 study
Byun1, JH; Ahn, JB; Kim, SY; Kang, JH; Zang, DY; Kang, SY; Kang, MJ; Shim, BY; Baek, SK; Kim, BS; Lee, KH; Lee, SI; Cho, SH; Sohn, BS; Kim, S; Hwang, IG; Nam, EM; Seo, BG; Oh, SC; Lee, MA; Lee, SC; Hong, JH; Park, YS

저서

저서 내용이 없습니다.

보도자료

신경내분비종양 표적항암제 '아피니토' PFS 연장
http://www.doctorsnews.co.kr/news/articleView.html?idxno=106445

[전문의 칼럼] 잡스가 걸렸던 신경내분비종양 보험급여 확대
http://joongang.joins.com/article/aid/2014/05/19/14293257.html?cloc=olink|article|default

[Health 특진실] 삼성서울병원 대장암센터
http://health.chosun.com/site/data/html_dir/2013/05/21/2013052101414.html

포스팅

포스팅 내용이 없습니다.

영상자료

영상자료 내용이 없습니다.

발표자료

발표자료 내용이 없습니다.